Back to search

Spain· ES:88816

MANIDIPINO AUROVITAS 20 MG COMPRIMIDOS EFG

A manidipine product containing manidipino, registered in Spain by Aurovitas Spain, S.A.U.. The same ATC class is registered in 5 of our 19 countries.

ATC C08CA11

Checked against AEMPS CIMA (Spain) on

Informational only — not a medical device.

SOURCE REGISTER · ESAEMPS CIMA (Spain)normalisedMANIDIPINO AUROVITAS 20 MG COMPRIMIDO…ATCC08CA11REGISTER NO.ES:88816PACKS LISTED1CHECKEDAugust 12, 2026

Where it is registered

Manidipine is registered in 5 of 19 countries.

Countries holding a registration under ATC C08CA11 (manidipine), each read from that country’s own register.

  • This record: Spain, from AEMPS CIMA (Spain)
  • 3 of them publish a price we can compare per daily dose

Manidipine · ATC C08CA11

5 / 19 countries

  • Franceprice
  • Italyprice
  • Japan
  • Spainprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of manidipine costs, country by country.

Normalised to the WHO defined daily dose (10 mg), the median price runs from $0.17 in France to $0.29 in Spain — a ×1.7 gap.

  • Spain: $0.29 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Manidipine · price per daily dose (10 mg)

USD · FX 28 Sept 2026

  • ES Spain$0.29
  • IT Italy$0.23
  • FR France$0.17
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

AEMPS CIMA (Spain)
Active substance
manidipino
Manufacturer
Aurovitas Spain, S.A.U.
Country
Spain (ES)
ATC code
C08CA11
ATC class
Manidipine
Defined daily dose
10 mg, O
Reimbursed
Not published by this register
Source register
AEMPS CIMA (Spain)
Last checked
August 12, 2026

Packs & prices · 1

1 priced
  • cima_codigo
    762671
    28
    EUR 14.17

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

1 interaction on record for manidipine.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Manidipine · interactions on record

1 record

1 more interaction with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Same medicine, other countries

Manidipine in 3 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All manidipine products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • France · Iperten, Manidipine Arrow
  • Greece · Manyper, Presidin
  • Italy · Erreman, Iperten
  • Portugal · Manidipina Generis

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of AEMPS CIMA (Spain). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ce1fe10a-d89d-4b19-b5bb-f84eb1629098
GET /v1/drugs/ce1fe10a-d89d-4b19-b5bb-f84eb1629098?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cpresc": "Medicamento Sujeto A Prescripción Médica",
  "estado": "{\"aut\":1682593581000}",
  "nregistro": "88816",
  "substance": "manidipino"
}

See everything about manidipine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.